By Divine Earth Theory | A Modern Apothecary
The hemp industry is facing its most consequential regulatory moment since the 2018 Farm Bill. On November 12, 2026, a sweeping redefinition of federal hemp law takes effect — one that will render the vast majority of hemp-derived products currently on the market legally non-compliant under the Controlled Substances Act.
We are not writing this to alarm you. We are writing this because transparency about what is happening — and why it validates every formulation decision we made — is exactly what our customers and this industry deserve.
Here is what is changing, why it matters, and what Divine Earth Theory's position is.
What Happened: The November 2025 Legislation
On November 12, 2025, Congress enacted the FY2026 Agriculture Appropriations Act (P.L. 119-37) — passed as part of the continuing resolution that ended the federal government shutdown. Buried inside an 800-plus page bill was Section 781: the most significant revision to hemp law since the 2018 Farm Bill removed hemp from the Controlled Substances Act entirely.
Section 781 takes effect exactly one year after enactment: November 12, 2026.
The Three Core Changes
1. From Delta-9 THC to Total THC
The 2018 Farm Bill defined legal hemp as cannabis with no more than 0.3% delta-9 THC by dry weight. This single focus on delta-9 THC created what critics called the "hemp loophole" — a legal pathway for intoxicating products made from other THC variants (delta-8, delta-10, THCA) to proliferate with minimal regulatory oversight.
Section 781 closes that loophole. Beginning November 2026, the federal definition of hemp will be based on total THC — including THCA and delta-8 — capped at 0.3% by dry weight. Products that relied on high THCA or converted delta-8 to stay under the delta-9 threshold will no longer qualify as hemp under federal law.
2. A Hard 0.4 Milligram Per Container Cap
This is the provision with the most sweeping industry impact. Any final hemp-derived cannabinoid product containing more than 0.4 milligrams of total THC per container will be excluded from the federal definition of hemp — and thus reclassified as marijuana under the Controlled Substances Act.
To understand how significant this is: products currently on the market typically contain between 2.5 and 10 milligrams of delta-9 THC per serving. The U.S. Hemp Roundtable has estimated this change alone would eliminate approximately 95% of existing hemp-derived cannabinoid products from the legal market. Even non-intoxicating "full-spectrum" CBD products, which naturally contain trace THC, are estimated to exceed this threshold in the vast majority of formulations currently sold.
3. Synthetic and Manufactured Cannabinoids Excluded
Products containing cannabinoids "synthesized or manufactured outside the plant" are explicitly excluded from the hemp definition — meaning the common practice of chemically converting CBD into delta-8 THC will be federally prohibited.
The FDA's Role: 90-Day Publication Requirements
The law directed the FDA to publish, within 90 days of enactment (by February 10, 2026):
- A complete list of cannabinoids naturally produced by Cannabis sativa L., as reflected in peer-reviewed literature
- A list of all THC-class cannabinoids known to occur naturally in the plant
- A list of cannabinoids with similar effects to — or marketed as having similar effects to — THC-class cannabinoids
- A regulatory definition of "container" as applied to hemp-derived products
These FDA determinations will meaningfully shape the practical scope of the new regulations. The definition of "container," in particular, will determine whether the 0.4 mg cap applies per package or per serving — a distinction with enormous formulation implications.
The Trump Executive Order: A Policy Signal, Not a Legal Shield
On December 18, 2025, President Trump signed Executive Order 14370, "Increasing Medical Marijuana and Cannabidiol Research" — directing the Attorney General to move marijuana from Schedule I to Schedule III under the Controlled Substances Act, and directing Congress to update the definition of hemp-derived cannabinoid products to preserve access to "appropriate full-spectrum CBD products" while restricting unsafe ones.
The Executive Order also established a Centers for Medicare & Medicaid Services (CMS) innovation model allowing Medicare beneficiaries to receive up to $500 annually in hemp-derived CBD products, when recommended by a physician, beginning in early 2026.
This is genuinely significant. A sitting president publicly acknowledging the medical value of hemp-derived CBD, directing federal agencies to create access pathways, and establishing Medicare reimbursement for CBD products is a landmark moment in the history of this plant.
However, as multiple legal analysts have made clear: the Executive Order does not delay, suspend, or supersede Section 781. Only Congress can change the law taking effect in November 2026. The EO is a powerful policy signal — and the right signal — but it does not provide legal protection for products that will exceed the statutory THC-per-container limit when that date arrives.
The 2026 Farm Bill: What the Agriculture Committee Said
In March 2026, the House Agriculture Committee passed the Farm, Food, and National Security Act of 2026 — the 2026 Farm Bill — by a 34-17 vote. The bill maintains the total THC standard for agricultural hemp, and Committee Chairman Glenn "GT" Thompson made his position unambiguous: regulation of final hemp-derived products is the jurisdiction of the House Committee on Energy and Commerce and the FDA — not the Agriculture Committee.
The 2026 Farm Bill includes positive provisions for industrial hemp farmers, including greater laboratory access for testing and more state flexibility. But it does not reverse the product restrictions coming in November.
The industry has one year. The clock is running.
What This Means for Most Hemp Brands
The honest assessment: the November 2026 changes will be catastrophic for a significant portion of the hemp industry as it currently exists.
Products built on delta-8, delta-10, THCA, or any formulation that naturally carries more than 0.4 mg of total THC per container — which is the vast majority of "full-spectrum" products currently on the market — will need to be reformulated, withdrawn, or face federal enforcement as Schedule I controlled substances.
Brands that have not already begun reformulation are operating against a hard deadline with an uncertain FDA guidance landscape.
Where Divine Earth Theory Stands
We formulated without intoxicating THC from day one. This was not a reaction to the regulatory changes announced in November 2025 — it was a conviction built into the company before those changes existed.
Total THC standard: Our aeroponic growing system, combined with FCE™ Full Cryosonic Extract technology, gives us precise control over cannabinoid profiles. We do not rely on THCA conversion or delta-8 chemistry. Our formulations are designed to the total THC standard.
0.4 mg per container cap: Our RESTORE formula is broad-spectrum and THC-free. Our REGENERATE formula is full-spectrum — and we are actively monitoring FDA's forthcoming "container" definition to ensure our formulation remains compliant with the final regulatory interpretation. We will publish our COAs and cannabinoid profiles openly.
Synthetic cannabinoids: We have never used converted or manufactured cannabinoids. Every compound in our formulas is naturally produced in the plant and captured through low-temperature extraction — not manufactured outside it.
We are pro-hemp, pro-research, and pro-transparency. We believe the regulations coming in November 2026 are, in their intent, the right direction for the industry: removing intoxicating, unregulated products from the market while preserving legitimate CBD wellness products. The execution details — particularly the 0.4 mg container cap — may need Congressional refinement. We support the Hemp Roundtable's advocacy for appropriate technical corrections that protect non-intoxicating CBD products while upholding the intent of the legislation.
But we are not waiting for Congress to build a compliant business. We already have one.
The Bigger Picture: Why Regulation Is Good for Serious Brands
The hemp industry's credibility problem is real. The proliferation of unregulated, inconsistently formulated, and in some cases genuinely deceptive products over the past seven years has damaged consumer trust and created legitimate public health concerns — particularly around products marketed to children and products with undisclosed intoxicating THC content.
The incoming regulations are a correction. They are imperfect — the 0.4 mg container cap is almost certainly too restrictive for some legitimate non-intoxicating products — but the direction is correct. Tighter standards. Cleaner labeling. Elimination of the synthetic THC loophole. These are good outcomes for consumers and for every brand that built a genuinely clean product.
The brands that survive November 2026 will be the ones that didn't need to reformulate in the first place. We are one of those brands.
What Consumers Should Know and Do Right Now
If you currently use hemp or CBD products, here are the questions worth asking:
1. Does this product contain delta-8, delta-10, or THCA? These compounds will be reclassified under federal law in November 2026. Products containing them may be in legal limbo by the end of the year.
2. Does the brand publish a full COA — including total THC, not just delta-9? If a brand is only reporting delta-9 THC and not total THC, you don't know what you're actually consuming. Ask for both numbers.
3. Is the brand formulating to the new standard proactively? A brand that is scrambling to reformulate today is a brand that built its products around regulatory arbitrage rather than genuine wellness science.
4. Is this product in the intoxicating category or the wellness category? The law is drawing that line clearly. Know which side of it the product you're taking falls on.
A Note on the Medicare CBD Pilot
One of the most underreported elements of President Trump's December 2025 Executive Order is the Medicare CBD pilot: a CMS Innovation Center model that will allow Medicare beneficiaries to receive up to $500 annually in hemp-derived CBD products, when recommended by a physician, beginning in early 2026.
This is the first time the federal government has established a payment pathway for hemp-derived CBD in a federal health program. The data this pilot generates — outcomes, safety, utilization — will inform long-term federal standards for CBD products and potentially open the door to broader insurance coverage.
For a plant that was a Schedule I controlled substance as recently as 2018, this represents a remarkable arc. We are watching this development closely.
Timeline Summary
| Date | Event | |------|--------| | November 12, 2025 | P.L. 119-37 enacted — the hemp redefinition law signed | | December 18, 2025 | Trump Executive Order 14370 signed — marijuana rescheduling directed, Medicare CBD pilot established | | February 10, 2026 | FDA deadline to publish cannabinoid lists and "container" definition | | Early 2026 | Medicare CBD pilot begins — up to $500/year for physician-recommended CBD | | March 2026 | House Agriculture Committee passes 2026 Farm Bill — product regulations remain under Energy & Commerce jurisdiction | | November 12, 2026 | Section 781 takes effect — new hemp definition and 0.4 mg/container THC cap become law |
The Bottom Line
The hemp industry is undergoing a regulatory reckoning that was inevitable. The 2018 Farm Bill opened a door without adequate guardrails, and eight years of inconsistent products — some genuinely excellent, many deeply problematic — followed. The correction was coming.
November 2026 is when it arrives.
Divine Earth Theory was built for this moment. Not because we predicted specific legislation, but because we refused to build a company on regulatory arbitrage. Clean source material. Transparent formulation. THC-free options designed to reach every market. Third-party testing at every batch.
We are pro-hemp. We believe in the plant's extraordinary potential. And we believe that potential is best served by a legal and commercial environment where only products that are genuinely clean, genuinely tested, and genuinely honest about what they contain can thrive.
That environment is almost here.
Want to stay ahead of the regulatory landscape? Join our waitlist for early access to products formulated to the new standard — and to receive updates as November 2026 approaches.
This article is for informational purposes only and does not constitute legal advice. Regulatory developments are ongoing and subject to change. Divine Earth Theory encourages all hemp industry participants and consumers to consult qualified legal counsel regarding compliance with federal and state hemp regulations.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Divine Earth Theory LLC